{"product_id":"aav-lacz-aav-aav-lacz-bhv21600444","title":"AAV-LacZ AAV (AAV-LacZ)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eAAV-LacZ AAV (AAV-LacZ) is an AAV vector available across multiple serotypes (AAV1, AAV2, AAV5) under the CMV promoter that delivers \u003cstrong\u003eβ-galactosidase (LacZ)\u003c\/strong\u003e to mammalian cells. Researchers commonly use this vector for reporter assay; in vivo gene delivery; cell labeling.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCapsid (serotype):\u003c\/strong\u003e available as AAV1, AAV2, AAV5. Tropism summary: AAV1 — broad transduction with notable activity in skeletal muscle, central nervous system (neurons), and retina; AAV2 — efficient neuronal transduction with limited spread; widely used for in vitro work and for focal CNS injections; AAV5 — efficient transduction of airway epithelium and CNS neurons; widely used in the brain.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePromoter:\u003c\/strong\u003e CMV — human cytomegalovirus immediate-early promoter; strong, broadly active in most mammalian cell types.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePayload:\u003c\/strong\u003e β-galactosidase (LacZ) — E. coli β-galactosidase; reports gene expression by enzymatic conversion of X-gal to a blue precipitate, enabling histochemical detection of transduced cells in tissue sections.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGenome backbone:\u003c\/strong\u003e Recombinant AAV (single-stranded unless explicitly noted as scAAV) flanked by AAV2 ITRs.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eβ-galactosidase (LacZ) is the \u003cem\u003eE. coli\u003c\/em\u003e–encoded enzyme that hydrolyzes lactose and a range of synthetic substrates. The chromogenic substrate X-gal is converted to a blue precipitate at sites of LacZ activity, allowing histochemical detection of transduced cells in fixed tissue sections.\u003c\/p\u003e\u003cp\u003eLacZ remains a valuable reporter when fluorescent imaging is impractical (e.g., highly autofluorescent tissue, archived FFPE sections) or when permanent staining of large tissue volumes is needed.\u003c\/p\u003e\u003cp\u003eThe CMV promoter — human cytomegalovirus immediate-early promoter; strong, broadly active in most mammalian cell types — drives expression of the payload from the AAV cassette in this product. Promoter–capsid combinations together determine where and at what level the payload is expressed.\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eReporter AAVs continue to be standard tools for benchmarking new capsid variants and engineered serotypes (e.g., directed evolution capsids, MyoAAV-class capsids, AAV.PHP-family capsids in mice).\u003c\/li\u003e\n\u003cli\u003eSingle-cell readouts (e.g., scRNA-seq, FACS) increasingly use reporter AAVs to define transduced populations within heterogeneous tissue.\u003c\/li\u003e\n\u003cli\u003eAAV vector engineering — including capsid evolution, capsid shuffling, and rational design — continues to expand the spectrum of accessible tissues and cell types.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eTracking transduction efficiency across cell types or tissue regions.\u003c\/li\u003e\n\u003cli\u003eBenchmarking new capsids or promoters in vitro and in vivo.\u003c\/li\u003e\n\u003cli\u003eActing as a labeling vector in dual-color experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eUse this product within experimental designs that include matched controls (capsid, promoter, dose, route) and a transduction validation step before interpreting payload-specific phenotypes.\u003c\/p\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eConfirm transduction efficiency in the target cell population before drawing payload-specific conclusions; reporter signal alone validates only that the vector reached and expressed in the cells.\u003c\/li\u003e\n\u003cli\u003eMatch AAV dose, capsid, promoter, and route across all conditions when comparing payload to control; differences in any of these confound payload-specific interpretation.\u003c\/li\u003e\n\u003cli\u003eAvoid repeated freeze–thaw cycles of AAV stocks — aliquot upon first thaw.\u003c\/li\u003e\n\u003cli\u003eAAV biology, including tropism, can differ between species, strains, ages, and routes — confirm in your specific system.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- Sources (internal):\n- Hall CV, Jacob PE, Ringold GM, Lee F. Expression and regulation of Escherichia coli lacZ gene fusions in mammalian cells. J Mol Appl Genet. 1983. https:\/\/pubmed.ncbi.nlm.nih.gov\/6310120\/\n- Schultz BR, Chamberlain JS. Recombinant adeno-associated virus transduction and integration. Mol Ther. 2008. https:\/\/www.cell.com\/molecular-therapy-family\/molecular-therapy\/fulltext\/S1525-0016(16)33063-5\n--\u003e","brand":"Vector Biolabs","offers":[{"title":"AAV1 \/ 1x10^13 GC\/ml \/ 20 µL","offer_id":53286541558125,"sku":"7001","price":495.0,"currency_code":"USD","in_stock":true},{"title":"AAV2 \/ 1x10^13 GC\/ml \/ 20 µL","offer_id":53286541590893,"sku":"7003","price":495.0,"currency_code":"USD","in_stock":true},{"title":"AAV5 \/ 1x10^13 GC\/ml \/ 20 µL","offer_id":53286581109101,"sku":"7005","price":495.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.ebiohippo.com\/products\/aav-lacz-aav-aav-lacz-bhv21600444","provider":"BioHippo","version":"1.0","type":"link"}